99.9% HIV-Free! Lenacapavir Shows Outstanding Results in Long-Acting PrEP Trial
Editor’s Note: On September 12, Gilead Sciences announced promising interim results from a pivotal Phase III trial evaluating the efficacy of Lenacapavir, a twice-yearly injectable HIV-1 capsid inhibitor, for the…